Analyst Consensus ?
ConsensusBuy23 ratings
Bullish1565.2%
Neutral730.4%
Bearish14.4%
1 unmapped firm rating excluded from the percentages.
The Cooper Companies, Inc. · COO · FY2026 Q2 · Calendar Q2 2026
Cooper Companies Q2: Record Revenue, Litigation Settlement, and CooperSurgical Strategic Review
Cooper Companies delivered its tenth consecutive consensus beat with record Q2 revenue of $1.08 billion (up 8% YoY) and non-GAAP EPS of $1.21 (up 26% YoY), driven by premium silicone hydrogel lens demand and fertility capital equipment strength. The stock surged 8.6% on the report with continued positive drift of 6.8% over subsequent sessions. Two major strategic developments reshape the company's forward profile: a $271.6 million settlement of the embryo culture media litigation covering over 95% of claimants, and the launch of a strategic review of the entire CooperSurgical segment with multiple interested parties. Management maintained full-year guidance despite a softer Asia-Pacific outlook while raising the free cash flow outlook to approximately $650 million, supported by AI-driven inventory optimization.
Reported After market closeNASDAQHealthcare
$14.17B market cap
90quality score
Company context
Snapshot as of publicationThe Cooper Companies, Inc. (COO) operates as a global medical device firm, primarily focused on developing, producing, and distributing products through two distinct business units: CooperVision and CooperSurgical. CooperVision specializes in contact lenses. Their product range includes spherical lenses for common vision issues like nearsightedness and farsightedness, as well as advanced lenses such as toric for astigmatism, multifocal for presbyopia, and specialized options addressing myopia, dry eyes, and eye fatigue.…
Earnings scorecard
Reported versus consensus
Reported EPS
$1.21
Consensus $1
EPS surprise
+10.0%
Reported versus consensus
Reported revenue
$1.08B
Consensus $1.05B
Revenue surprise
+2.6%
Reported versus consensus
Earnings History
Estimate
Beat
Miss
Match
Analyst 52W Price Targets
$72.65Previous close
$61Low
$104.5Average
$368High
Latest persisted target per named analyst; persisted previous close from FN2's market snapshot as of Jul 31, 2026. Not an FN2 forecast.
Firm-level rating actions
FMP grade actions identify the grading firm, not a named analyst.
| Firm | Rating | Prior rating | Action | Date |
|---|---|---|---|---|
| Citigroup | Neutral | Neutral | Maintain | Jul 8, 2026 |
| BNP Paribas | Outperform | Outperform | Maintain | Jun 8, 2026 |
| Wells Fargo | Equal Weight | Equal Weight | Maintain | Jun 5, 2026 |
| Stifel | Buy | Buy | Maintain | Jun 5, 2026 |
| Needham | Buy | Buy | Maintain | Jun 5, 2026 |
| JP Morgan | Neutral | Neutral | Maintain | Jun 5, 2026 |
| Baird | Outperform | Outperform | Maintain | Jun 5, 2026 |
| Mizuho | Outperform | Outperform | Maintain | Jun 4, 2026 |
| Piper Sandler | Overweight | Overweight | Maintain | Jun 1, 2026 |
| Barclays | Overweight | Overweight | Maintain | Mar 6, 2026 |
| Morgan Stanley | Equal Weight | Equal Weight | Maintain | Dec 8, 2025 |
| Goldman Sachs | Sell | Sell | Maintain | Dec 8, 2025 |
| Redburn Atlantic | Neutral | Buy | Downgrade | Oct 4, 2023 |
| Jefferies | Hold | Buy | Downgrade | Oct 11, 2022 |
| Keybanc | Overweight | Downgrade | Aug 28, 2022 | |
| Stephens & Co. | Overweight | Overweight | Maintain | Jun 2, 2022 |
| Guggenheim | Buy | Neutral | Upgrade | Jan 2, 2022 |
| Raymond James | Outperform | Outperform | Maintain | Mar 4, 2021 |
| Oppenheimer | Perform | Perform | Maintain | Sep 3, 2020 |
| BMO Capital | Outperform | Outperform | Maintain | Mar 5, 2019 |
| Cleveland Research | Buy | Neutral | Upgrade | May 15, 2016 |
| PiperJaffray | Overweight | Overweight | Maintain | Dec 4, 2015 |
| Stifel Nicolaus | Buy | Buy | Maintain | Dec 1, 2015 |
| Morgan Keegan | Outperform | Outperform | Maintain | Mar 8, 2012 |
Named analyst price targets
Upside is calculated against the persisted previous close $72.65. FMP does not supply a rating on these named-analyst rows.
| Firm | Analyst | 52W target | Price when posted | Upside | Date |
|---|---|---|---|---|---|
| Needham | David Saxon | $86 | $62.02 | +18.4% | Jun 5, 2026 |
| Wells Fargo | Larry Biegelsen | $66 | $62.02 | -9.2% | Jun 5, 2026 |
| Mizuho Securities | Anthony Petrone | $85 | $60.34 | +17.0% | Jun 4, 2026 |
| Piper Sandler | Analyst unavailable | $86 | $61.21 | +18.4% | Jun 1, 2026 |
| Goldman Sachs | Analyst unavailable | $61 | $62.03 | -16.0% | May 27, 2026 |
| Needham | Analyst unavailable | $99 | $80.65 | +36.3% | Feb 3, 2026 |
| Barclays | Analyst unavailable | $98 | $81.29 | +34.9% | Jan 26, 2026 |
| Goldman Sachs | Analyst unavailable | $73 | $83.13 | +0.5% | Jan 9, 2026 |
| Goldman Sachs | Analyst unavailable | $71 | $81.4 | -2.3% | Dec 8, 2025 |
| Barclays | Matt Miksic | $91 | $81.4 | +25.3% | Dec 8, 2025 |
| Robert W. Baird | Analyst unavailable | $98 | $77.03 | +34.9% | Dec 5, 2025 |
| Mizuho Securities | Analyst unavailable | $100 | $77.03 | +37.6% | Dec 5, 2025 |
| Stifel Nicolaus | Jonathan Block | $95 | $77.03 | +30.8% | Dec 5, 2025 |
| Piper Sandler | Analyst unavailable | $94 | $77.03 | +29.4% | Dec 5, 2025 |
| Needham | David Saxon | $100 | $77.03 | +37.6% | Dec 5, 2025 |
| Barclays | Matt Miksic | $85 | $68.37 | +17.0% | Oct 13, 2025 |
| Goldman Sachs | David Roman | $64 | $68.56 | -11.9% | Oct 1, 2025 |
| Robert W. Baird | Jeff Johnson | $85 | $66.18 | +17.0% | Aug 28, 2025 |
| Morgan Stanley | Patrick Wood | $76 | $64.77 | +4.6% | Aug 28, 2025 |
| Stifel Nicolaus | Analyst unavailable | $85 | $64.58 | +17.0% | Aug 28, 2025 |
| Needham | David Saxon | $94 | $69.55 | +29.4% | Jun 17, 2025 |
| Stifel Nicolaus | Analyst unavailable | $105 | $85 | +44.5% | Mar 7, 2025 |
| Robert W. Baird | Analyst unavailable | $107 | $85 | +47.3% | Mar 7, 2025 |
| Jefferies | Young Li | $115 | $90.14 | +58.3% | Jul 16, 2024 |
| Piper Sandler | Jason Bednar | $115 | $90.23 | +58.3% | May 31, 2024 |
| Robert W. Baird | Jeff Johnson | $118 | $90.23 | +62.4% | May 31, 2024 |
| Mizuho Securities | Anthony Petrone | $110 | $93.34 | +51.4% | Aug 28, 2023 |
| Piper Sandler | Analyst unavailable | $375 | $351.02 | +416.2% | Jan 11, 2023 |
| Citigroup | Analyst unavailable | $368 | $315.67 | +406.5% | Dec 12, 2022 |
| Robert W. Baird | Jeff Johnson | $375 | $311.32 | +416.2% | Aug 24, 2022 |
| Stifel Nicolaus | Jonathan Block | $450 | $316.79 | +519.4% | Jun 14, 2022 |
| Wells Fargo | Larry Biegelsen | $480 | $442.01 | +560.7% | Aug 19, 2021 |
| Jefferies | Raj Denhoy | $112.5 | $98.61 | +54.9% | May 24, 2021 |
Track every rating change on COO the moment it posts. Free to start.
Start freeMarket reaction
event-close to next-session close
Stock move
+8.6%
Event window
SPY move
-2.6%
Same window
Abnormal move
+11.2%
Stock minus SPY
Volume
3.3×
Versus trailing sessions
Subsequent drift
+6.8%
Up to 20 sessions
COOSPY benchmark
Follow COO with an agent that reads every filing, transcript, and price print. Free to start.
Try FN2 freeTranscript intelligence
What changed
Revenue reached a record $1.08 billion, beating the $1.054 billion consensus by 2.6%. Non-GAAP EPS of $1.21 exceeded the $1.10 estimate by 10%, marking the tenth straight quarter above consensus. Free cash flow totaled $96 million, and the FY2026 free cash flow outlook was raised to approximately $650 million. The company settled the December 2023 embryo culture media litigation for a $271.6 million charge excluded from non-GAAP results, covering over 95% of claimants. A strategic review of CooperSurgical is underway with multiple parties expressing interest in the entire business or its components, and a definitive update is expected before the next earnings call. Asia-Pacific contact lens demand remained soft, prompting a modest downward revision to regional guidance.
Guidance delta
Full-year FY2026 guidance was maintained, with organic growth targets of 3.5 to 4.5 percent for CooperVision and 4 to 5 percent for CooperSurgical. The free cash flow outlook was raised to approximately 650 million dollars. A modest downward revision was made to Asia-Pacific regional guidance, offset by strength elsewhere. EPS guidance was left unchanged despite the strong first-half performance, drawing analyst questions.
Key takeaways
- Record Q2 revenue of $1.08 billion (up 8% YoY) and non-GAAP EPS of $1.21 (up 26% YoY), beating consensus for the 10th consecutive quarter.
- Free cash flow of $96 million; FY2026 free cash flow outlook raised to approximately $650 million.
- Embryo culture media litigation settled for $271.6 million (non-GAAP charge), covering over 95% of claimants.
- Strategic review of CooperSurgical launched with multiple interested parties; definitive update expected before next earnings call.
- Asia-Pacific contact lens market remains soft, prompting a modest downward revision to regional guidance.
Management priorities
- Complete the CooperSurgical strategic review and provide a definitive update before the next earnings call.
- Launch Clariti toric and multifocal lenses in Japan and broaden the Clariti rollout across EMEA and Asia-Pacific.
- Expand MyDay MiSight myopia-control franchise in Europe and Japan.
- Roll out AI-driven inventory optimization across the business to reduce inventory and boost free cash flow.
- Accelerate share repurchases once the strategic review progresses.
Related earnings events
HealthcareSources
- Earnings call transcript and parsed analysis · 2026-06-05T09:18:06.223174+00:00
- FN2 earnings calendar · 2026-07-26T00:37:12.209961+00:00
- Polygon adjusted daily market bars · 2026-07-31T10:51:33.266395+00:00
- Financial Modeling Prep analyst price-target consensus and quote snapshot · 2026-07-31T10:51:33.264055+00:00
Methodology
Reported and consensus figures come from FN2's earnings event records. Market reaction and volume are calculated from daily adjusted bars around the event; abnormal move subtracts the SPY move over the same window.
Analyst target low, average, and high values are derived at request time from each named analyst's latest persisted FMP target. The current-price marker comes from FN2's persisted market snapshot. They are sell-side estimates, not an FN2 valuation or recommendation.
Transcript intelligence is a structured synthesis of the current and prior earnings-call analyses. Missing values stay missing and are never estimated.
By FN2 Research · Updated . For educational purposes only; not investment advice.